ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00334828|
Recruitment Status : Completed
First Posted : June 8, 2006
Last Update Posted : July 25, 2017
|Condition or disease||Intervention/treatment||Phase|
|Severe Sepsis||Drug: eritoran tetrasodium Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis|
|Study Start Date :||June 2006|
|Actual Primary Completion Date :||January 2011|
Drug: eritoran tetrasodium
Intravenous infusion at a total dose of 105 mg.
|Placebo Comparator: 2||
Matching placebo; intravenous infusion.
- All-cause mortality at Day 28. [ Time Frame: 28 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00334828
|Study Director:||Dan Rossignol||Eisai Inc.|